Zota Health Care Ltd
Zota Health Care Limited is a renowned pharmaceutical company that manufactures, markets, and exports pharmaceutical, ayurvedic, nutraceutical, and over-the-counter (OTC) products across boundaries into the semi-regulated and regulated markets of Asian Countries markets of African Countries, Russian Countries & Latin America.[1]
- Market Cap ₹ 1,237 Cr.
- Current Price ₹ 478
- High / Low ₹ 555 / 272
- Stock P/E 372
- Book Value ₹ 47.5
- Dividend Yield 0.21 %
- ROCE 8.76 %
- ROE 6.66 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Stock is trading at 10.1 times its book value
- Promoter holding has decreased over last quarter: -1.70%
- Company has a low return on equity of 6.55% over last 3 years.
- Earnings include an other income of Rs.2.14 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
38 | 43 | 49 | 56 | 64 | 70 | 77 | 85 | 95 | 106 | 131 | 138 | 155 | |
33 | 37 | 43 | 47 | 55 | 60 | 66 | 77 | 90 | 105 | 116 | 130 | 149 | |
Operating Profit | 5 | 6 | 7 | 8 | 10 | 10 | 11 | 8 | 5 | 1 | 15 | 8 | 6 |
OPM % | 13% | 14% | 13% | 15% | 15% | 14% | 14% | 9% | 5% | 1% | 12% | 6% | 4% |
0 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | |
Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 3 | 3 | 2 | 3 |
Profit before tax | 3 | 4 | 5 | 6 | 8 | 8 | 11 | 8 | 4 | -0 | 14 | 9 | 5 |
Tax % | 33% | 32% | 33% | 33% | 34% | 34% | 36% | 29% | 29% | 47% | 25% | 24% | |
2 | 3 | 3 | 4 | 5 | 6 | 7 | 6 | 3 | -0 | 11 | 7 | 4 | |
EPS in Rs | 1.41 | 1.52 | 1.86 | 2.12 | 2.54 | 2.76 | 2.96 | 2.26 | 1.12 | -0.07 | 4.21 | 2.62 | 1.48 |
Dividend Payout % | 50% | 47% | 38% | 34% | 28% | 52% | 72% | 32% | 89% | -1,535% | 36% | 38% |
Compounded Sales Growth | |
---|---|
10 Years: | 12% |
5 Years: | 12% |
3 Years: | 13% |
TTM: | 16% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | -3% |
3 Years: | 31% |
TTM: | -47% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 20% |
3 Years: | 46% |
1 Year: | 67% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 6% |
3 Years: | 7% |
Last Year: | 7% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 10 | 12 | 12 | 14 | 14 | 14 | 18 | 18 | 25 | 25 | 25 | 25 | 26 |
Reserves | 3 | 2 | 4 | 4 | 7 | 13 | 52 | 51 | 44 | 42 | 66 | 69 | 97 |
6 | 5 | 5 | 5 | 2 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
10 | 10 | 13 | 15 | 20 | 23 | 22 | 21 | 20 | 19 | 34 | 30 | 29 | |
Total Liabilities | 28 | 29 | 33 | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 152 |
10 | 9 | 9 | 8 | 7 | 7 | 10 | 10 | 15 | 14 | 13 | 11 | 39 | |
CWIP | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 2 | 0 | 0 | 0 | 3 | 4 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 16 | 14 | 10 | 35 | 10 | 0 |
19 | 20 | 24 | 30 | 36 | 45 | 56 | 63 | 59 | 62 | 78 | 101 | 109 | |
Total Assets | 28 | 29 | 33 | 38 | 44 | 54 | 92 | 90 | 88 | 86 | 125 | 125 | 152 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
5 | 3 | 3 | 4 | 5 | 3 | -4 | -3 | 6 | -1 | 14 | -10 | |
-3 | -1 | -1 | -1 | -1 | -2 | -26 | 9 | -4 | 4 | -27 | 13 | |
-2 | -2 | -2 | -4 | -3 | -2 | 33 | -6 | -3 | -2 | 14 | -4 | |
Net Cash Flow | -0 | 0 | 0 | 0 | 1 | -1 | 2 | -1 | -1 | 1 | 1 | -1 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 71 | 71 | 79 | 77 | 90 | 88 | 109 | 95 | 112 | 99 | 107 | 115 |
Inventory Days | 141 | 132 | 134 | 175 | 141 | 193 | 174 | 207 | 139 | 139 | 116 | 148 |
Days Payable | 90 | 86 | 104 | 116 | 126 | 148 | 118 | 103 | 82 | 77 | 76 | 102 |
Cash Conversion Cycle | 123 | 117 | 108 | 135 | 105 | 133 | 165 | 199 | 169 | 161 | 147 | 161 |
Working Capital Days | 86 | 86 | 74 | 87 | 85 | 115 | 151 | 175 | 152 | 143 | 112 | 153 |
ROCE % | 21% | 24% | 27% | 32% | 36% | 33% | 23% | 11% | 6% | -2% | 18% | 9% |
Business segments
Domestic sales (49% of FY21 revenue)[1] The is the oldest division and involves direct distribution of generic drugs, OTC products, and other pharmaceutical products through Company’s distribution network across India. Co. has 1050+ distributors across India and 3000+ products in its portfolio.